Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna®, a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that the Company will report financial results for the three months ended March 31, 2014 after the close of trading on Wednesday, May 14th. The company will also conduct a conference call and webcast to discuss financial results and provide a corporate update at 5:00 P.M. EDT on Wednesday, May 14th.
Help employers find you! Check out all the jobs and post your resume.
